Last reviewed · How we verify

NCT01054859

A PHASE I, A SINGLE-CENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, THREE-PERIOD, THREE-WAY CROSSOVER STUDY OF THE HEMODYNAMIC INTERACTIONS OF AVANAFIL AND ALCOHOL IN HEALTHY MALE SUBJECTS

Completed Phase 1 Last updated 5 January 2011
What this trial tests

Phase 1 trial testing avanafil in Erectile Dysfunction in 15 participants. Completed in 1 January 2010.

Timeline
1 January 2010
Primary endpoint
1 January 2010
1 January 2010

Quick facts

Lead sponsorVIVUS LLC
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment15
Start date1 January 2010
Primary completion1 January 2010
Estimated completion1 January 2010

Drugs / interventions tested

Conditions studied

Sponsor

VIVUS LLC — full company profile →

Who can join

Adults 21 to 45, male only, with Erectile Dysfunction. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is primarily to evaluate whether taking avanafil with alcohol causes the blood pressure to fall.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

Other VIVUS LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01054859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing